Every 10-Q that PharmaCyte Biotech, Inc. (PMCB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PMCB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMCB filings page.
PharmaCyte Biotech, Inc. (PMCB) reported no revenue and a net loss attributable to common stockholders of $5.8 million (loss per share $0.54) for the three months ended July 31, 2026, an improvement from an $8.4 million loss ( $1.23 per share) a year earlier, driven largely by changes in fair values of investments and warrant-related liabilities. Operating expenses remained modest for a biotech, with $60,000 in R&D and $946,708 in G&A.
Total assets fell to $36.7 million from $46.8 million, mainly from declines in the fair value of the Q/C Technologies (QCLS) preferred stock and warrants, which generated combined noncash losses of about $8.7 million, and Femasys positions. Cash and cash equivalents were $17.7 million, and management expects roughly $17 million of cash at filing to fund operations for at least 12 months, but additional capital will be needed to complete a pancreatic cancer trial. The FDA’s clinical hold on the LAPC program remains in place while extensive preclinical, manufacturing, and device-compatibility work continues, and a Business Review Committee has curtailed program spending amid dependence on SG Austria. PMCB also remains out of compliance with Nasdaq’s $1.00 minimum bid price and has shareholder approval for a potential reverse stock split to regain compliance.
PharmaCyte Biotech reported financial results for the three and nine months ended January 31, 2026, as it continues developing its Cell-in-a-Box-based cancer therapies while its pancreatic cancer program remains on FDA clinical hold. The company generated no revenue, reflecting its development-stage status.
For the quarter, PharmaCyte recorded net income of $746,860, driven mainly by fair value gains on investments and warrant-related items, but a net loss attributable to common stockholders of $1.56 million, or $0.17 per share, after preferred stock accretion and dividends. For the nine months, the loss attributable to common stockholders was $18.33 million, or $2.41 per share.
As of January 31, 2026, the company held $20.2 million in cash and cash equivalents and total assets of $55.9 million, including sizable fair value investments in Femasys and Q/C Technologies preferred shares and warrants. Stockholders’ equity declined to $38.1 million, while warrant and derivative liabilities increased to $14.8 million, reflecting the liability classification of these instruments.
Operating cash outflow for the nine months was $3.76 million, partly offset by $2.0 million of net investing inflows and $6.75 million of financing inflows from the August 2025 Series C convertible preferred stock and warrant financing and warrant exercises. Management states that current cash is expected to fund projected operating requirements for at least twelve months, but additional capital will be needed to complete a pancreatic cancer clinical trial and broader development plans, and equity or debt financing could be dilutive or restrictive.
PharmaCyte Biotech, Inc. reports results for the three and six months ended October 31, 2025, showing no revenue and a larger accounting-driven loss as it reshapes its balance sheet. Net loss attributable to common stockholders was $8.4M for the quarter and $16.8M for the six months, compared with income of $17.6M in the prior-year period, mainly due to swings in fair values of warrants and preferred stock investments rather than operating costs. Cash and cash equivalents were $15.4M and total assets $56.0M, while warrant liabilities increased to $16.2M.
The company raised $7.0M by issuing 7,000 shares of Series C convertible preferred stock with attached warrants and invested $3.0M in Q/C Technologies (QCLS) Series H preferred shares and warrants, recording a $2.1M initial gain. It also holds a $5.0M Femasys note, now at par and subsequently repaid in cash, plus Femasys equity and warrants. Management expects about $20.9M of cash, including the Femasys repayment, to fund operations for at least 12 months, but still anticipates needing additional capital to run a pancreatic cancer clinical trial.